Drugs / Clinolipid
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04555044 | Jan 2021 → Oct 2022 | metabolic disease | Baxter Healthcare Corporation | Completed | No outcome recorded |
| Phase 4 | NCT02476994 | May 2015 → Oct 2016 | metabolic disease | Baxter Healthcare Corporation | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Clinolipid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04555044 ↗ |
| Modality | Other / unclassified | “Lipid injectable emulsion, USP 20%” NCT04555044 ↗ |
| Route | Intravenous | “Study treatment will be administered intravenously” NCT04555044 ↗ |